Abstract

Concerns have been raised about the potential influence of political pressures on drug funding decisions. We evaluated the temporal relationship between cancer drug funding and provincial elections in 9 Canadian provinces. New indications for cancer drugs between January 2003 and December 2012 were identified, and the dates of official provincial funding dates and election dates between 1 January 2003 and 31 December 2014 were retrieved. The probability of drug funding announcements in the 60-day period preceding a provincial election was evaluated using binomial probability distribution analysis. Data from 9 provinces (all Canadian provinces except Quebec) were available. During the period of interest, 69 new indications for 39 individual drugs were identified. Variation in the availability of funding dates was identified. At the time of data collection, 2 provinces did not have data available for all 69 indications. For the 9 provinces, the number of funded indications during the 60-day period preceding an election ranged from 0 to 3; however, no differences in the proportion of indications funded pre-election were identified. Additional analyses also failed to demonstrate any significant associations with the 90-day period before an election, or the 60- and 90-day periods after an election. We observed no clear temporal relationship between provincial election dates and funding decisions in this recent Canadian sample of new indications for cancer drugs.

Highlights

  • Cancer drugs are increasing in both number and cost[1]

  • Drug funding dates in each province for the identified indications and provincial election dates were gathered for the period 1 January 2003 to 31 December 2014

  • Our study demonstrates that a systematic use of political influence via elections is not occurring, published evidence has shown that, in certain situations, politicization affects cancer drug funding[7]

Read more

Summary

Introduction

Cancer drugs are increasing in both number and cost[1]. Internationally, governments face challenges prioritizing funding decisions[2,3]. In Canada, national evidence-based reviews have been standardized to evaluate the efficacy and cost-effectiveness of new cancer agents[6]. Evidence of efficacy is necessary, multiple other factors can influence the decision to fund a drug at the provincial level[3,7]. Potential external factors include the influence of media, patient advocates, politicians, and the pharmaceutical industry[7]. Involvement of those various policy actors was discussed in a study examining Ontario’s funding of trastuzumab, a cancer drug used to treat breast cancer, compared with a number of other cancer drugs[7]. We evaluated the temporal relationship between cancer drug funding and provincial elections in 9 Canadian provinces

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call